More vaccine hope

More hype than HOPE.

More Hype Than HOPE To the Editor: In the recently published Heart Outcomes Prevention Evaluation (HOPE study),1 treatment with the ACE inhibitor ramipril was reported to reduce cardiovascular morbidity and mortality independent of blood pressure (BP) reduction. High-risk “normotensive” (BP 140/80 mm Hg) patients (n 9541) were randomized to receive either 10 mg of ramipril or placebo in additio...

Less hype, more hope.

A Boosted Hope — AIDS Vaccine Research

Medical and Scientific Advisory Committee Bisher Akil, M.D. Peter Anton, M.D. H. Aaron Aronow, M.D. Victor Beer, M.D. Aron Bick, M.D. Joseph Church, M.D. Gary Cohan, M.D. Richard Cooper, M.D. Jim Corti, R.N. George Fareed, M.D. Erik Fleishman, D.O. Jonathan Goldsmith, M.D. Michael Gottlieb, M.D. Edward Grant, M.D. David Hardy, M.D. David Hart, M.D. Scott Hitt, M.D. John James Wilbert Jordan, M....

More Than a Glimmer of Hope

See related article, pages 3009–3016. Stroke unit care, intravenous thrombolysis, and endovascular treatment of acute ischemic stroke have changed stroke medicine dramatically. In the past decades, the chances of surviving acute ischemic stroke without severe handicap have increased substantially for the majority of stroke patients. However, the outlook for patients with intracerebral hemorrhag...

Challenges and Perspectives toward Development of more Effective Influenza Vaccine

Influenza viruses continue to be a major health threat in human and bird populations. The improvements in formulation and production level of the current influenza vaccines are not sufficient to afford complete protection. The continuous antigenic drifts and emergence of endemic and zoonotic strains make influenza vaccine planning difficult. Concern about the emergence of new influenza pandemic...